8 results about "Gastric Disorders" patented technology

The invention discloses a long-acting pellet suitable for gastric absorption and a preparation method of the long-acting pellet. The long-acting pellet is prepared from the following components in parts by mass: 0.01-1 part of a medicine, 1-2.5 parts of a filler, 0.2-0.7 part of a modified pore-foaming agent mixture, 1-2.5 parts of an improved adhesive mixture and 0.1-0.7 part of an improved sonokinetic response agent. Wherein the modified pore-foaming agent mixture is prepared from a modified pore-foaming agent and glycosylated saponin, the modified pore-foaming agent is prepared by mixing a pore-foaming agent and seleno-amino acid according to a mass ratio of 4: 1, the improved adhesive is mixed with the adhesive through BHP-SH, and ionic crosslinking is performed by using CaCl2 to form a covalent ion dual network, so that the stomach adhesiveness is enhanced; the sonokinetic response agent is improved by the coated poria cocos extract, and the long-acting pellet is prepared by adopting a wet granulation method or a fluidized bed method, has the characteristics of slow release, long acting, targeted stomach absorption and responsive drug release, and is suitable for treating stomach diseases such as gastritis.

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The application discloses a kind of biological hybrid micro machine population oral delivery system of imitating Helicobacter pylori survival mechanism, belong to oral stomach medicine delivery technical field.The system is by active power module (flagellum driven chlamydomonas reinhardtii), environmental regulation module (acid urease modified on algal surface) and multifunctional load module (macrophage membrane wrapped drug-loaded nanoparticles) synergistic assembly through polydopamine (PDA) spatial conformation control layer is formed.Active power module utilizes self-movement ability to penetrate mucus barrier and extend intracavity retention time to 12 hours or more;Environmental regulation module produces local alkalization effect by catalyzing urea hydrolysis, provides chemical shield for system in extremely acid environment of pH 1.0-3.0, protects active power module from gastric acid inactivation;Multifunctional load module is accurately delivered to gastric epithelial cells by inflammation targeting effect, such as CRISPR / Cas9 biological macromolecule, and realizes up to 31.8% in-vivo gene editing efficiency.The application provides a non-invasive, modular active delivery platform for the precise treatment of gastric diseases such as gastritis through the synergistic effect of physical penetration, metabolic reprogramming and gene intervention.

This invention discloses a high-load XOR tumor-targeting therapy nanoplatform based on ROS activity and its applications, belonging to the field of nanobiomaterials. This high-load XOR tumor-targeting therapy nanoplatform, using a zeolite imidazole framework-8 (ZIF-8) as a carrier, contains xanthine oxidoreductase (XOR) with cellular enzymatic activity. It possesses the ability to target tumor cells and induce intracellular reactive oxygen species (ROS), leading to tumor cell death. Induction of intracellular ROS in tumor macrophages (TAMs) also supports the differentiation of macrophages into M1 types. ROS-induced apoptosis in tumor cells produces a series of tumor-associated antigens, which further promotes the infiltration and activation of macrophages in the tumor microenvironment. This, in turn, leads to increased infiltration of CD8+ T cells in the tumor, whose cytokine profile shows cytotoxic effects, indicating successful induction of an adaptive anti-tumor response. This novel nanomaterial offers a promising new strategy for the immunotherapy of gastric diseases.

The application discloses a short-wave ultraviolet irradiation-based stomach disease treatment instrument, and belongs to the technical field of medical equipment.The application comprises a treatment instrument main body, a main pipe body, a probe end, an ultraviolet emission end and a treatment control module for controlling the treatment instrument main body; the modular design of the treatment instrument main body and the combination with the ultraviolet emission end improve the clinical operability and treatment effect, the combination with the rotary toothed disc driving mechanism enables the ultraviolet emission end to realize all-around twisting, covers the stomach area, the light-transmitting layer blocks infrared radiation while ensuring the ultraviolet transmittance, reduces the thermal stimulation on the stomach tissue, and enables medical staff to observe the irradiation effect in real time, realizes visual treatment, the treatment control module realizes the precision and intelligence of stomach disease treatment through a multi-unit cooperative architecture, generates a personalized scheme based on the disease type and the lesion position, monitors the physiological indexes of patients in real time and dynamically adjusts the treatment parameters, and improves the treatment safety and effectiveness.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The invention provides application of a genetic regulation molecular axis in gastric lesion evolution discrimination and drug screening, and belongs to the technical field of biological medicines. The specific dynamic expression track of the lnc517368 / miR-203b-3p / SMAD2 axis in gastric lesion evolution is disclosed and defined for the first time, and brand new molecular basis and objective standard are provided for stage discrimination of gastric diseases. Meanwhile, an intervention strategy taking the axis as a target is defined, and a reliable screening and evaluation system is established for developing drugs for blocking or reversing the progress of stomach lesion. And by taking a turbid-dissolving and detoxifying formula as an example, reversible intervention of a disease evolution trajectory can be realized by adjusting the shaft, so that the method not only has important scientific theoretical value, but also shows wide conversion and application prospects in the aspects of disease diagnosis, drug research and development, clinical treatment strategy formulation and the like.